Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient interferon beta-1a (exclusively for subcutaneous use), ATC L03AB07 for the period November 1st, 2024 - October 31st, 2026
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
Section 130a paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for the medicines to be supplied at the expense of the statutory health insurance companies. With regard to the relevant legal regulations for the awarding of public contracts, a regular process of active ingredient-related, formal procurement procedures takes place in accordance with the regulations of Part 4 of the GWB by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract for the above-mentioned. Active ingredient, interferon beta-1a (for subcutaneous use only
Related Procurement Opportunities
Similar tenders in Pharmaceuticals